Trastuzumab
Jump to navigation
Jump to search
A monoclonal antibody against the ErbB-2 receptor that lengthens remission time in metastatic breast cancer.[1]
References
- ↑ Hudis CA (2007). "Trastuzumab--mechanism of action and use in clinical practice.". N Engl J Med 357 (1): 39-51. DOI:10.1056/NEJMra043186. PMID 17611206. Research Blogging.